50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,719.04
DOW   29,683.74
QQQ   279.94
Mullen Automotive Is Ready To Get In Gear
How You Should Be Choosing Your Stocks (Ad)pixel
You Don't Have to Go It Alone. It's Time to Let Go and Let Others Help.
Cracker Barrel: A Tasty Treat Or Bad Apple? 
How You Should Be Choosing Your Stocks (Ad)pixel
Alzheimer's drug shows promise in early results of study
Can United Natural Foods Fight Both Inflation and the Fed?
How You Should Be Choosing Your Stocks (Ad)pixel
Bank of England to buy UK bonds to avert financial risk
Russia prepares to annex occupied Ukraine despite outcry
S&P 500   3,719.04
DOW   29,683.74
QQQ   279.94
Mullen Automotive Is Ready To Get In Gear
How You Should Be Choosing Your Stocks (Ad)pixel
You Don't Have to Go It Alone. It's Time to Let Go and Let Others Help.
Cracker Barrel: A Tasty Treat Or Bad Apple? 
How You Should Be Choosing Your Stocks (Ad)pixel
Alzheimer's drug shows promise in early results of study
Can United Natural Foods Fight Both Inflation and the Fed?
How You Should Be Choosing Your Stocks (Ad)pixel
Bank of England to buy UK bonds to avert financial risk
Russia prepares to annex occupied Ukraine despite outcry
S&P 500   3,719.04
DOW   29,683.74
QQQ   279.94
Mullen Automotive Is Ready To Get In Gear
How You Should Be Choosing Your Stocks (Ad)pixel
You Don't Have to Go It Alone. It's Time to Let Go and Let Others Help.
Cracker Barrel: A Tasty Treat Or Bad Apple? 
How You Should Be Choosing Your Stocks (Ad)pixel
Alzheimer's drug shows promise in early results of study
Can United Natural Foods Fight Both Inflation and the Fed?
How You Should Be Choosing Your Stocks (Ad)pixel
Bank of England to buy UK bonds to avert financial risk
Russia prepares to annex occupied Ukraine despite outcry
S&P 500   3,719.04
DOW   29,683.74
QQQ   279.94
Mullen Automotive Is Ready To Get In Gear
How You Should Be Choosing Your Stocks (Ad)pixel
You Don't Have to Go It Alone. It's Time to Let Go and Let Others Help.
Cracker Barrel: A Tasty Treat Or Bad Apple? 
How You Should Be Choosing Your Stocks (Ad)pixel
Alzheimer's drug shows promise in early results of study
Can United Natural Foods Fight Both Inflation and the Fed?
How You Should Be Choosing Your Stocks (Ad)pixel
Bank of England to buy UK bonds to avert financial risk
Russia prepares to annex occupied Ukraine despite outcry
NASDAQ:WVE

Wave Life Sciences - WVE Stock Forecast, Price & News

$3.78
+0.13 (+3.56%)
(As of 09/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.66
$4.13
50-Day Range
$2.37
$3.92
52-Week Range
$1.16
$5.53
Volume
410,771 shs
Average Volume
434,250 shs
Market Capitalization
$328.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Wave Life Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
111.6% Upside
$8.00 Price Target
Short Interest
Healthy
1.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.40mentions of Wave Life Sciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.24) to ($1.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

120th out of 1,096 stocks

Pharmaceutical Preparations Industry

42nd out of 548 stocks

WVE stock logo

About Wave Life Sciences (NASDAQ:WVE) Stock

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

WVE Stock News Headlines

Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates
U.S. Stocks Turn Higher; Athira Pharma Shares Plummet
Wave Life Sciences to raise $70M in stock offering
WAVE Life Sciences Earnings Preview
Wave Life Sciences Q1 2022 Earnings Preview
See More Headlines
Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

WVE Company Calendar

Last Earnings
8/11/2022
Today
9/28/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:WVE
Employees
235
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+111.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-122,250,000.00
Net Margins
-297.98%
Pretax Margin
-298.49%

Debt

Sales & Book Value

Annual Sales
$40.96 million
Book Value
$0.55 per share

Miscellaneous

Free Float
58,864,000
Market Cap
$328.18 million
Optionable
Optionable
Beta
-0.55

Key Executives

  • Dr. Paul B. Bolno M.B.A. (Age 48)
    M.D., MBA, Pres, CEO & Director
    Comp: $994.61k
  • Dr. Chandra Vargeese Ph.D. (Age 61)
    Chief Technology Officer
    Comp: $656.06k
  • Dr. Michael A. Panzara M.D. (Age 55)
    M.P.H., MPH, Chief Medical Officer and Head of Therapeutics Discovery & Devel.
    Comp: $692.94k
  • Mr. Kyle B. Moran CFA (Age 51)
    CFO & Principal Accounting Officer
  • Kate Rausch
    Head of Investor Relations
  • Ms. Linda Rockett J.D.
    Gen. Counsel
  • Ms. Anne-Marie Li-Kwai-Cheung
    Sr. VP of Regulatory Affairs, Compliance & Policy
  • Dr. Christopher Francis Ph.D. (Age 44)
    Sr. VP of Corp. Devel. & Head of Emerging Areas
  • Mr. Jonathan Rosin
    Chief HR Officer
  • Dr. Sridhar Vaddeboina Ph.D.
    Sr. VP of Chemistry, Manufacturing & Controls













WVE Stock - Frequently Asked Questions

Should I buy or sell Wave Life Sciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" WVE shares.
View WVE analyst ratings
or view top-rated stocks.

What is Wave Life Sciences' stock price forecast for 2022?

1 brokers have issued 12-month target prices for Wave Life Sciences' stock. Their WVE share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next year. This suggests a possible upside of 111.6% from the stock's current price.
View analysts price targets for WVE
or view top-rated stocks among Wall Street analysts.

How have WVE shares performed in 2022?

Wave Life Sciences' stock was trading at $3.14 at the start of the year. Since then, WVE stock has increased by 20.4% and is now trading at $3.78.
View the best growth stocks for 2022 here
.

When is Wave Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our WVE earnings forecast
.

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd. (NASDAQ:WVE) posted its quarterly earnings data on Thursday, August, 11th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.06. The company earned $0.38 million during the quarter, compared to analysts' expectations of $3.25 million. Wave Life Sciences had a negative trailing twelve-month return on equity of 515.04% and a negative net margin of 297.98%.

What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?

17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).

What is Wave Life Sciences' stock symbol?

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

How do I buy shares of Wave Life Sciences?

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Wave Life Sciences' stock price today?

One share of WVE stock can currently be purchased for approximately $3.78.

How much money does Wave Life Sciences make?

Wave Life Sciences (NASDAQ:WVE) has a market capitalization of $328.18 million and generates $40.96 million in revenue each year. The company earns $-122,250,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.

How many employees does Wave Life Sciences have?

The company employs 235 workers across the globe.

How can I contact Wave Life Sciences?

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The official website for the company is www.wavelifesciences.com. The company can be reached via phone at (656) 236-3388, via email at krausch@wavelifesci.com, or via fax at 617-949-2901.

This page (NASDAQ:WVE) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.